Ireland passes legislation for reference pricing of drugs and increased generics use

29 May 2013

Irish Parliamentarians last week passed the country’s Health (Pricing and Supply of Medical Goods) Bill 2012 through both Houses of the Oireachtas, moves that were welcomed by Health Minister James Reilly and Alex White, Minister of State with responsibility for Primary Care in the Department of Health.

Minister Reilly said: “This legislation gives effect to the commitment in the Program for Government that reference pricing and greater use of generics would be introduced to reduce the state’s large drug bill and the cost to individuals of their medicines. It will promote price competition and deliver lower medicine prices for both the state and patients.”

Minister White added: “The Bill permits pharmacists to substitute medicines which have been designated as interchangeable by the Irish Medicines Board. It is only where the IMB is satisfied that a medicinal product satisfies all the conditions set out in the Bill that it can do so. To further enhance patient safety, the Bill allows a prescriber to indicate on a prescription that a branded interchangeable medicinal product should, for clinical reasons, not be substituted.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics